https://pipelinereview.com/sellas-life-sciences-announces-completion-of-enrollment-in-phase-2-randomized-controlled-clinical-study-of-nelipepimut-s-plus-trastuzumab-in-high-risk-high-expression-her2-breast-cancer-patients/